<?xml version="1.0" encoding="UTF-8"?>
<p>An international group of experts has also issued recommendations with particular reference to TB treatment trials: pregnant and lactating women should be eligible for Phase III MDR TB trials unless a compelling reason for exclusion exists, drug companies should be encouraged to complete reproductive toxicity studies of TB drugs before beginning Phase III studies, trials of shortened treatment regimens for latent TB infection (LTBI) should be designed to improve completion rates and reduce risk of progression in pregnancy and lactation, targeted PK studies should be nested in all TB studies when evidence is lacking, and a TB pregnancy registry should be established to accumulate data on maternalâ€“infant outcomes [
 <xref rid="pmed.1002882.ref006" ref-type="bibr">6</xref>]. These were discussed at the March 2018 WHO technical consultation discussions, and the following propositions were made.
</p>
